Echinocandins for Management of Invasive Candidiasis in Patients with Liver Disease and Liver Transplantation

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2018 Jun 9

PMID 29881298

Citations 6

Authors

Siang Fei Yeoh

Tae Jin Lee

Ka Lip Chew

Stephen Lin

Dennis Yeo

Sajita Setia

Affiliations

Soon will be listed here.

Abstract

species remains one of the most important causes of opportunistic infections worldwide. Invasive candidiasis (IC) is associated with considerable morbidity and mortality in liver disease (LD) patients if not treated promptly. Echinocandins are often recommended as a first-line empirical treatment for managing IC and can especially play a critical role in managing IC in LD patients. However, advanced LD patients are often immunocompromised and critically ill. Hence altered pharmacokinetics, drug interactions as well as tolerance issues of antifungal treatments are a concern in these patients. This comprehensive review examines the epidemiology, risk factors and diagnosis of IC in patients with LD and evaluates differences between three available echinocandins for treating this group of patients.

Citing Articles

Drug-drug interaction between tacrolimus and caspofungin in Chinese kidney transplant patients with different genotypes.

Zhang Y, Shen B, Li Y, Zong H, Zhang X, Cao X Ther Adv Drug Saf. 2024; 15:20420986241243165.

PMID: 38646424 PMC: 11027596. DOI: 10.1177/20420986241243165.

: Pathogenicity and Resistance Mechanisms for Adaptation and Survival.

Hassan Y, Chew S, Than L J Fungi (Basel). 2021; 7(8).

PMID: 34436206 PMC: 8398317. DOI: 10.3390/jof7080667.

Treatment Practices for Adults With Candidemia at 9 Active Surveillance Sites-United States, 2017-2018.

Gold J, Seagle E, Nadle J, Barter D, Czaja C, Johnston H Clin Infect Dis. 2021; 73(9):1609-1616.

PMID: 34079987 PMC: 8609664. DOI: 10.1093/cid/ciab512.

Pre-Existing Liver Disease and Toxicity of Antifungals.

Spernovasilis N, Kofteridis D J Fungi (Basel). 2018; 4(4).

PMID: 30544724 PMC: 6309049. DOI: 10.3390/jof4040133.

Therapy of Non-Dermatophytic Mycoses in Animals.

Elad D J Fungi (Basel). 2018; 4(4).

PMID: 30380772 PMC: 6308939. DOI: 10.3390/jof4040120.

References

Mikulska M, Del Bono V, Ratto S, Viscoli C . Occurrence, presentation and treatment of candidemia. Expert Rev Clin Immunol. 2012; 8(8):755-65. DOI: 10.1586/eci.12.52. View

Muilwijk E, Lempers V, Burger D, Warris A, Pickkers P, Aarnoutse R . Impact of special patient populations on the pharmacokinetics of echinocandins. Expert Rev Anti Infect Ther. 2015; 13(6):799-815. DOI: 10.1586/14787210.2015.1028366. View

Chakravarty-Vartak U, Taklikar S, Baradkar V, Vartak S, Bhatt N . Peritonitis due to Candida albicans in a patient with chronic hepatitis C infection. Saudi J Gastroenterol. 2009; 14(3):147. PMC: 2702922. DOI: 10.4103/1319-3767.41736. View

Avni T, Leibovici L, Paul M . PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2010; 49(2):665-70. PMC: 3043518. DOI: 10.1128/JCM.01602-10. View

Lin C, Liu C, Hsieh F, Lee C, Wang W . Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan. J Microbiol Immunol Infect. 2014; 48(5):552-8. DOI: 10.1016/j.jmii.2014.07.007. View

Tascini C, Sozio E, Corte L, Sbrana F, Scarparo C, Ripoli A . The role of biofilm forming on mortality in patients with candidemia: a study derived from real world data. Infect Dis (Lond). 2017; 50(3):214-219. DOI: 10.1080/23744235.2017.1384956. View

Dupont H, Paugam-Burtz C, Muller-Serieys C, Fierobe L, Chosidow D, Marmuse J . Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg. 2002; 137(12):1341-6; discussion 1347. DOI: 10.1001/archsurg.137.12.1341. View

DU Q, Wang Z, He L, Jiang X, Wang L . PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol. 2013; 69(11):1917-25. DOI: 10.1007/s00228-013-1552-2. View

Tan T, Tan A, Tee N, Ng L, Chee C . The increased role of non-albicans species in candidaemia: results from a 3-year surveillance study. Mycoses. 2009; 53(6):515-21. DOI: 10.1111/j.1439-0507.2009.01746.x. View

10.

Snydman D . Shifting patterns in the epidemiology of nosocomial Candida infections. Chest. 2003; 123(5 Suppl):500S-3S. DOI: 10.1378/chest.123.5_suppl.500s. View

11.

Thursz M, Richardson P, Allison M, Austin A, Bowers M, Day C . Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015; 372(17):1619-28. DOI: 10.1056/NEJMoa1412278. View

12.

Leber B, Spindelboeck W, Stadlbauer V . Infectious complications of acute and chronic liver disease. Semin Respir Crit Care Med. 2012; 33(1):80-95. DOI: 10.1055/s-0032-1301737. View

13.

Eschenauer G, DePestel D, Carver P . Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2008; 3(1):71-97. PMC: 1936290. DOI: 10.2147/tcrm.2007.3.1.71. View

14.

Mistry G, Migoya E, Deutsch P, Winchell G, Hesney M, Li S . Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol. 2007; 47(8):951-61. DOI: 10.1177/0091270007303764. View

15.

Lahmer T, Messer M, Schwerdtfeger C, Rasch S, Lee M, Saugel B . Invasive mycosis in medical intensive care unit patients with severe alcoholic hepatitis. Mycopathologia. 2014; 177(3-4):193-7. DOI: 10.1007/s11046-014-9740-x. View

16.

Ernst E, Klepser M, Pfaller M . Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother. 2000; 44(4):1108-11. PMC: 89826. DOI: 10.1128/AAC.44.4.1108-1111.2000. View

17.

Ahlquist Cleveland A, Harrison L, Farley M, Hollick R, Stein B, Chiller T . Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One. 2015; 10(3):e0120452. PMC: 4378850. DOI: 10.1371/journal.pone.0120452. View

18.

Cholongitas E, Senzolo M, Patch D, Kwong K, Nikolopoulou V, Leandro G . Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther. 2006; 23(7):883-93. DOI: 10.1111/j.1365-2036.2006.02842.x. View

19.

Lepak A, Castanheira M, Diekema D, Pfaller M, Andes D . Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Antimicrob Agents Chemother. 2012; 56(11):5875-82. PMC: 3486567. DOI: 10.1128/AAC.01102-12. View

20.

Nguyen T, Hoppe-Tichy T, Geiss H, Rastall A, Swoboda S, Schmidt J . Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother. 2007; 60(1):100-6. DOI: 10.1093/jac/dkm125. View